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Abstract
Background: Estimates suggest that up to 30% of colorectal cancers (CRC) may develop due to an increased genetic 
risk. The mean age at diagnosis for CRC is about 70 years. Time of disease onset 20 years younger than the mean age is 
assumed to be indicative of genetic susceptibility. We have compared high resolution tumor genome copy number 
variation (CNV) (Roche NimbleGen, 385 000 oligo CGH array) in microsatellite stable (MSS) tumors from two age 
groups, including 23 young at onset patients without known hereditary syndromes and with a median age of 44 years 
(range: 28-53) and 17 elderly patients with median age 79 years (range: 69-87). Our aim was to identify differences in 
the tumor genomes between these groups and pinpoint potential susceptibility loci. Integration analysis of CNV and 
genome wide mRNA expression data, available for the same tumors, was performed to identify a restricted candidate 
gene list.
Results: The total fraction of the genome with aberrant copy number, the overall genomic profile and the TP53 
mutation spectrum were similar between the two age groups. However, both the number of chromosomal aberrations 
and the number of breakpoints differed significantly between the groups. Gains of 2q35, 10q21.3-22.1, 10q22.3 and 
19q13.2-13.31 and losses from 1p31.3, 1q21.1, 2q21.2, 4p16.1-q28.3, 10p11.1 and 19p12, positions that in total contain 
more than 500 genes, were found significantly more often in the early onset group as compared to the late onset 
group. Integration analysis revealed a covariation of DNA copy number at these sites and mRNA expression for 107 of 
the genes. Seven of these genes, CLC, EIF4E, LTBP4, PLA2G12A, PPAT, RG9MTD2, and ZNF574, had significantly different 
mRNA expression comparing median expression levels across the transcriptome between the two groups.
Conclusions: Ten genomic loci, containing more than 500 protein coding genes, are identified as more often altered in 
tumors from early onset versus late onset CRC. Integration of genome and transcriptome data identifies seven novel 
candidate genes with the potential to identify an increased risk for CRC.
Background
Less than five percent of all patients diagnosed with col-
orectal cancers (CRC) carry known genetic germline
alterations that predispose to the disease [1]. However, it
has been estimated that up to 30% of all CRC patients
may carry a genetic risk as suggested by young age at
onset, multiple tumors in the same patient, and an excess
of individuals with CRC within a family [2,3]. Many stud-
ies have tried to identify some of these genetic risk fac-
tors, and several recent genome-wide association studies
(GWAS) have pinpointed SNP loci on chromosome arms
8q, 10p, 11q, 14q, 15q, 16q, 18q, 19q, and 20p to be asso-
ciated with CRC [4-10]. Furthermore, a study by Mourra
et al. [11] showed that microsatellite loci within chromo-
some arm 14q, known to be deleted in about 30% of all
colorectal cancers, were more frequently lost in tumors
from early onset patients.
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TP53 mutations and genomic copy number alterations,
as well as other somatic genetic and epigenetic altera-
tions, have been shown to accumulate with the adenoma-
carcinoma development in CRC [12-17]. Copy number
alterations are typically identified using cytogenetic tech-
niques as G-banding, chromosome-based comparative
genomic hybridization (cCGH) and array-CGH (aCGH)
[18]. For the most common chromosomal aberrations,
which include gains at 7q, 7p, 8q, 11q, 13q, and 20q and
losses from 1p, 4p, 4q, 8p, 14q, 15q, 17p, and 18, the time
of occurrence in the adenoma-carcinoma sequence has
been suggested [16,17,19]. In addition, cCGH has been
used to identify DNA sequences that contain predispos-
ing genes, e.g. changes in chromosome 19 found in
tumors from patients with Peutz-Jeghers syndrome, led
to the identification of STK11 as the predisposition gene
[20]. Other susceptibility loci and genes have been sug-
gested for CRC, typically based on linkage analyses and
genome wide SNP analyses [10,21-28].
Array-CGH allows for increased resolution, improves
the chromosome dependent method, and thus facilitates
detection of small aberrations and fine-tunes the accu-
racy of breakpoint determination [29]. In order to iden-
tify somatic differences and potential susceptibility loci
for CRC, we have compared high resolution (385 000
oligo probe array) DNA copy number profile and TP53
mutation status in carcinomas from late onset and early
onset patients without known hereditary CRC syn-
dromes. These data have further been integrated with
corresponding gene expression data for each patient.
Methods
Patients and tumor samples
Forty patients diagnosed with CRC, were included in the
study. Patient gender and age, and tumor stage and loca-
tion are shown in Table 1 and Additional file 1. Twenty-
three patients with early onset CRC were enrolled from 4
different hospitals in the south-eastern region of Norway.
HNPCC, FAP and other known syndromes were
excluded after a thorough family and medical history.
Seventeen patients with late onset CRC, treated in one of
the hospitals, were selected after matching for sex, tumor
location and stage.
Tissue samples were taken and preserved in the opera-
tion theatre immediately after resection of the specimen.
In the early onset group samples were transferred to
tubes with RNA-later RNA Stabilization Reagent (Qia-
gen, Hilden, Germany), stored at room temperature over
night, then transferred to an empty tube and frozen at -
80°C for long-term storage. In the late onset group sam-
ples were frozen in liquid nitrogen and stored at -80°C
until use.
Written informed consent was obtained from all sub-
jects included. The research biobanks are registered
according to national legislation and the research project
is approved by the Regional Committee for Medical
Research Ethics (REK South-East: 1.2005.1629; REK
South: 2003, S-02126).
Nucleic acids isolation
The tumor tissue was manually ground in liquid N2 using
a mortar and pestle before isolation of DNA. DNA was
extracted using a semi-automatic phenol-chloroform
extraction method followed by ethanol precipitation in a
340A Nucleic Acid Extractor (Applied Biosystems, Foster
City, CA, USA). Ensuring good DNA quality, DNA was
measured by using NanoDrop ND-1000 (Thermo Fisher
Scientific, Waltham, MA, USA). Samples with OD 260
nm/280 nm >1.7 were included. Thereafter, the DNA was
diluted in TE-buffer to a final concentration of 250 ng/μl.
The integrity of the DNA was visually inspected on a 1%
agarose gel.
RNA was isolated using AllPrep DNA/RNA mini kit
(Qiagen). The RNA quality and quantity was measured
using the NanoDrop ND-1000 and OD 260 nm/280 nm
and OD 260 nm/230 nm was carefully evaluated. Degra-
dation was measured using BioAnalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA). All samples included
had RNA concentrations above 150 ng/μl, and RNA
integrity number (RIN) above 8.0.
Microsatellite instability analysis
MSI status was determined for all tumors and positive
samples were excluded from further analyses, in order to
avoid any potential undetected HNPCC patient. Deter-
mination of MSI status was performed as described by
Wu et al.[30], using the Bethesda markers. High degree of
microsatellite instability (MSI-H) was defined if two or
more markers showed aberrant profile after fragment
analysis.
Array Comparative Genomic Hybridization (aCGH)
From each sample, 1 μg DNA was included in the analysis
alongside with gender-matched human reference DNA.
Each of the two reference samples, one female and one
male reference, consisted of a pool of DNA from normal
lymphocytes from four healthy persons. The applied
microarray platform, Roche NimbleGen, Human Whole-
Genome Array CGH Analysis v1 (Roche Diagnostics,
Mannheim, Germany), provides measurements from 385
000 unique genomic loci. The aCGH experimental proce-
dure, as well as raw data pre-processing and normaliza-
tion, was performed by NimbleGen Systems Inc. at their
facility in Iceland [31,32]. For mapping of genomic break-
points the segMNT v1.1 CGH segmentation analysis
algorithm were run in NimbleScan™ software v2.4
(Roche, Basel, Switzerland). A window-size of approxi-Berg et al. Molecular Cancer 2010, 9:100
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mately 60 000 base pairs, calculating the average of 10
probes per window, was further used for analysis.
The female reference pool was hybridized against the
male reference pool as a technical control. To determine
the threshold for scoring of gain and loss, normalized,
log2-transformed ratios were used. Based on the variation
in autosomal genomic regions, which should not vary
between the two reference samples, thresholds for aver-
aged log2 ratio data were set to 0.1 and -0.1 for gains and
losses, respectively. For the control experiment this
implied a false positive rate per genomic loci of .005 and
.007 for gains and losses, respectively. As expected when
hybridizing female DNA vs. male DNA, gain was seen for
the whole of chromosome × whereas loss was seen for the
whole of chromosome Y. Furthermore, two samples were
run twice on two different arrays. For each doublet of
samples the squared correlation coefficient (R2) was cal-
culated from all measurements if one or both samples dif-
fered from normal copy number. The two samples
showed correlation coefficient of 0.84 and 0.75, respec-
tively. For pairs of random samples the correlation coeffi-
cient was calculated in the same manner. Median
correlation coefficient for ten pairs of random samples
was 0.16 (range 0.04 - 0.32).
Statistical differences in frequencies of gains and losses,
between the groups of early onset and late onset CRC
patients, were calculated using Fisher's exact test. Signifi-
cance values were for each window/segment calculated
based on number of patients with gain or loss compared
to no-gain and no-loss, respectively. Affected telomere
regions and regions spanning centromeres were not con-
sidered as these regions have highly repetitive fragments
and may reflect changes that are technical in nature. Also,
changes in sex chromosomes were not considered. The
number of chromosomal aberrations and the number of
breakpoints were calculated as follows: A chromosomal
aberration spanning an entire chromosome was recorded
as one chromosomal aberration and zero breakpoints; a
chromosomal aberration inside a chromosome was
recorded as one chromosomal aberration and two break-
points.
To assign the corresponding chromosome band to
specified breakpoints, and identify genes included in
given regions we used the UCSC Genome Browser (Mar.
2006 (hg18) assembly, URL: http://www.genome.
ucsc.edu) and BioMart genome annotation tool (version
0.7, Ensemble version 53, URL: http://www.biomart.org/
), respectively.
Integration of DNA copy numbers to gene expression data
Genome-wide measurements of mRNA levels were
obtained by AB1700 gene expression microarrays
(Applied Biosystems, Foster City, CA, USA). Information
on sample handling and preprocessing of the raw data
will be published elsewhere (Ågesen et al., manuscript in
preparation). For the integration analysis, we used quan-
t i l e  n o r m a l i z e d  d a t a  w i t h  g e n e - w i s e  c e n t e r i n g  o n  t h e
median of the dataset.
Table 1: Summary of patient data in the early and late onset CRC series.
Early onset (n = 23) Late onset (n = 17)
n%n% p-value
Male 10 43.5 9 52.9
Female 13 56.5 8 47.1 0.75#
Average age 43.2 78.6
Median age 44.0 79.0
min, age 28 69
max, age 53 87 <0.01§
Dukes' A 41 7 . 452 9 . 4
Dukes' B 52 1 . 752 9 . 4
Dukes' C 10 43.5 5 29.4
Dukes' D 41 7 . 42 1 1 . 8  0 0 . 6 9 #
Proximal colon 62 6 . 131 7 . 6
Distal colon 17 73.9 14 82.4 0.71#
# Fisher's exact test
§ Student's t-testBerg et al. Molecular Cancer 2010, 9:100
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Each measurement on the mRNA expression array was
related to the DNA copy number status of the corre-
sponding genomic loci. A visual basic (VBA) script was
written to automate the analyses and to perform inte-
grated statistics genome-wide on a gene-by-gene and
locus-by-locus manner. For each gene, and for gain, loss
and normal copy number independently, the median of
the expression levels for the samples with the DNA copy
number changes was divided by the median of the
expression levels for the samples with normal copy num-
ber. To indicate genes with concomitant gain and over-
expression, we set a threshold at 1.5, and genes with con-
comitant loss and under-expression were indicated when
the value was below 0.75. Furthermore, the expression
levels for genes located in regions with statistically signif-
icant difference in gain or loss in the early onset com-
pared to the late onset CRC samples, were evaluated
using Independent samples T-test in SPSS. Annotations
of genes are used according to AB1700 annotation file
(version; 20060930_ab1700_human, Applied Biosystems).
Overview of the study is given in Figure 1.
TP53 mutation analysis
The total protein coding region of TP53 was amplified in
a multiplex PCR reaction containing five distinct PCR
fragments by using flanking intronic primers with M13
tails. Multiplex PCR kit was used as recommended by the
vendor (Qiagen, Hilden, Germany). If initial multiplex
PCR reaction did not succeed, the same fragments were
amplified separately using each of the primer pairs.
Primer and fragment details are described in Additional
file 2. After visual inspection of quality and quantity on a
polyacrylamide gel, the product was purified using Exo-
SAP-IT (USB Corporation, Cleveland, OH, USA).
Sequencing of the purified products was performed in
both 5'- and 3' directions using BigDye Terminator v3.1
kit (Applied BioSystems, Foster City, CA, USA). Primers
for the sequencing reaction were identical with those
used in the initial PCR for fragments amplified in multi-
plex reactions. M13-primers were used in sequencing
reactions of singleplex PCR products. The resulting
sequence product was further purified using multiscreen
plates, (MilliPore, Billerica, MA, USA) with Sephadex™
G-50 Superfine (GE Healthcare, Chalfont St. Giles, UK),
and subjected to sequencing at a 3730 DNA Analyzer
(Applied Biosystems, Foster City, CA, USA). If a mutation
was detected, a new independent PCR product was sub-
jected to sequencing to confirm our finding.
Results
Genomic profile of colorectal carcinomas
The profile of DNA copy number gains and losses across
all samples is shown in Figure 2A. Overall, across the 40
MSS colorectal samples the median number of chromo-
somal aberrations was 31.5 (range 11-93), and the median
percentage of probes showing normal copy number was
78% (range 48%-99%).
Gains at 8q, 13q and 20q and losses from 4p, 4q, 8p,
17p, 18p and 18q were most frequent (range 43%-78%).
Aberrations in the p-arm of acrocentric chromosomes
were not considered as these most probably reflect tech-
nical challenges. The most frequent loss, 18q22.1-22.3
affecting ~10 Mbps, was found in 78% of all samples. This
region comprises 34 protein coding genes. The region
most often gained, found in 70% of the tumors, were a
~7.5 Mbps region at 20q13.31-13.33. This region contains
10 miRNAs and 100 genes. One of the most commonly
affected chromosomes, chromosome 8, showed losses
from the p-arm in 65% of all tumors and gains at the q-
arm in 43%. For the majority of the samples, the break-
point between gain and loss at chromosome 8 was
located in the p-arm, about 5 Mbps away from the cen-
tromere, as shown in Additional file 3.
Genomic profiles of early onset versus late onset colorectal 
carcinomas
The average fraction of the genome with aberrant copy
number was similar in the early onset and late onset CRC
series, 26% versus 22%, respectively (P = 0.53). However,
both the number of chromosomal aberrations and thus
the number of breakpoints differed significantly between
the groups (P = 0.02 and P = 0.01, respectively). Chromo-
some regions with aberrations are listed in Table 2. Over-
view of aberrations from each patient sample is shown in
Additional file 4.
A plot of gains and losses along a genome axis for each
of the two patient groups shows distinct differences (Fig-
ure 2B). Statistical calculations suggested that 3.2% of the
genome was significantly different between the two
groups. This includes 16 different regions at 6 unique
chromosomes, spans a total of 58.3 Mbps, and affects 107
genes, (Figure 3). Four regions with statistical significant
difference were spanning centromere regions and were
excluded from further analysis. Only 0.3 Mbps of these
changes (one region) were more often observed in late
onset cancers than in the early onset group (Table 2). The
parts of the genome that exhibited significant difference
between the two tumor groups contains, among others,
574 protein coding genes, 44 miRNA, and 47 pseudo-
genes, as listed in Additional file 5.
Overall, the smallest region of overlap (SRO) of losses
with the most statistically significant difference between
early onset and late onset patients (P = 0.003) was located
0.24 Mbps adjacent to the centromere in chromosome 4.
Only one miRNA maps to this position. Fourteen of the
23 (61%) early onset CRC patients, as compared to two of
17 (12%) late onset patients, displayed loss in this region.
The most significant SRO of losses containing proteinBerg et al. Molecular Cancer 2010, 9:100
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Figure 1 Study design comparing the tumor genomes of early onset and late onset colorectal cancer patients. Tumor samples from early on-
set and late onset CRC patients were analyzed with aCGH (DNA/genome level) and the data were integrated with the mRNA expression (RNA/tran-
scriptome level) of the same samples. About 10 000 genes show corresponding DNA and RNA level. Exclusion of genes located outside chromosomal 
regions with statistically significant difference between the two patient groups resulted in 107 genes, summarized in Additional file 6. Further, exclu-
sion of genes whose mRNA expression levels were not statistically significant between patients groups resulted in a short list of seven potential pre-
disposing genes, as summarized in Table 3.
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Figure 2 Genomic profile across all chromosomes from 40 tumor samples. A) Copy number profile across all 40 colorectal carcinomas, including 
early onset (n = 23) and late onset (n = 17) tumors. Percentage of samples with gains is shown in red and losses in green. Gains and losses in the short 
arm of acrocentric chromosomes are not considered and further discussed. The centromere positions are indicated by dashed lines, and changes re-
corded at the p-arms and q-arms are shown to the left and right of the dashed lines, respectively. B) Copy number profiles of early onset (solid) as 
compared to late onset (line) colorectal carcinomas.
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coding genes was located at 1q21.1 (P = 0.01). This posi-
tion contains one protein coding gene, namely PRKAB2,
encoding a regulatory subunit of the AMP-activated pro-
tein kinase (AMPK). Ten of 23 (43%) early onset CRC
patients, and only one of 17 (6%) late onset patients, dis-
played loss of this locus.
Copy number differences between the patient groups
were found for large parts of chromosome 4 (4p16.1-
q28.3) (Figure 2B). In total, the regions on chromosome 4
with significant differences between the groups con-
tained 258 protein coding genes, 36 miRNAs and 27
pseudogenes.
Two sequence stretches within 10q22.3 and 19q13.31
were gained in 8 of 23 patients in the early onset group
versus none among the 17 late onset patients (P = 0.01).
The 10q region contains four protein coding genes,
SFTPA2, ZCCHC24, PPIF and ZMIZ1, whereas the 19q
region includes only PSG3  (pregnancy-specific beta-1-
glycoprotein 3). At chromosome 19 a 4 Mbps gained
region (19q13.2-q13.31) was significantly more frequent
in the early onset group. This comprises 103 protein cod-
ing genes and three miRNAs. The protein coding genes
include, among others, a group of genes in the carcino-
embryonic antigen (CEA) family.
Only one region, spanning 0.3 Mbps at 5q13.2, was
gained more often in late onset patients (5 of 17) com-
pared to early onset patients (none of 23). The region
contains 4 putative protein coding genes, β-clucoroni-
dase-like protein SMA5, β-clucoronidase-like protein
SMA4, ENSG00000205565, and ENSG00000197370.
Integrated genome and transcriptome analysis
An integration analysis of the DNA copy number data
and mRNA expression data revealed that 37% (~10 900)
of the genes had corresponding DNA copy number and
RNA expression levels. Among these, 107 genes were
located in genomic regions with significantly different
frequency of copy number changes between the two
tumor groups (Additional file 6). When sorting these 107
genes based on fold-change of expression levels between
the groups, CLC,  CEACAM7,  FCGBP, hGC1641029.5
(Probe ID:218092) and CD79A were top five for gains,
and the top five list for losses included LOC391661(Probe
ID:152373),  ARSJ,  ADH6, SPP1  and  BANK1. From the
107 genes, those with significantly different mRNA
expression levels between the early onset and late onset
groups were identified. The resulting strict gene list
included seven genes (Table 3 and Figure 3). Of these,
three genes (CLC, LTBP4 and ZNF574), all within chro-
Table 2: Genomic loci with statistically significant copy number variation between early and late onset colorectal cancers.
Chromosome Band Mbps from pter Size (Mbps) p-value (average)
Gain
2 q35 217.2 3.2 0.03
5* q13.2 69.5 0.3 0.03
10 q21.3-22.1 70.9 2.4 0.02
10 q22.3 79.5 1.5 0.01
19 q13.2-13.31 44.6 3.9 0.02
Loss
1 p31.3 61.5 0.3 0.02
1 q21.1 145.02 0.6 0.02
2 q21.2 132.78 0.1 0.02
4 p16.1 8.88 0.7 0.02
4 p14 39.6 1.0 0.05
4 q21.3-22.1 88.02 0.4 0.02
4 q22.1-28.2 88.44 41.1 0.04
4 q28.2-28.3 129.96 2.0 0.05
4 q28.3 132.96 0.3 0.03
10 p11.1 38.94 0.1 0.03
19 p12 20.52 0.3 0.03
*Aberration is significantly more often present in the late onset than the early onset patients.Berg et al. Molecular Cancer 2010, 9:100
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mosome band 19q13.2, were concomitantly gained and
up-regulated, and four genes (PPAT, EIF4E, RG9MTD2
and  PLA2G12A) were lost and down-regulated. The
PPAT gene is located in 4q21, EIF4E and RG9MTD2 in
4q23 and PLA2G12A in 4q25. The expression levels for
each gene are shown in Figure 4.
TP53 mutations and genetic complexity
Mutation status of TP53  was evaluated for all protein
coding exons. Sixty-five percent of the samples were
mutated, with no significant difference being observed in
the early onset group compared to the late onset group
(Additional file 1). Five percent of the mutations were
located outside the DNA binding domain of TP53. A
region frequently lost at 17p comprises the p13.1 band
where the TP53 gene is encoded. Loss in this region was
observed in 55% of the tumor samples, also with no fre-
quency difference between the early onset and the late
onset group. Overall, 80% of the samples displayed muta-
tion in TP53  and/or DNA copy number aberration of
17p13.1. Both loss of 17p13.1 and mutation in TP53 were
independently associated with an increased number of
chromosomal aberrations (P < 0.01 and P < 0.01, respec-
tively, and P = 0.03 for loss and mutation combined). This
difference was still significant when comparing mutated
(n = 9) and wild type (n = 8) samples with normal copy
number in 17p13.1 only (P = 0.01).
The concurrent loss and reduced expression of PPAT,
EIF4E,  RG9MTD2, and PLA2G12A, were significantly
correlated to TP53 mutations (P = 0.006) in the tumors
from the early onset patients. The same trend was seen
for tumors with concurrent gain and elevated expression
of CLC, LTBP4 and ZNF574, though not statistically sig-
nificant, (P = 0.17).
Discussion
In Norway, around 5% of all patients with CRC are diag-
nosed before the age of 55. However, the incidence rate
increases with increasing age, and the median age at diag-
nosis is 70 years. Individuals with early onset of CRC may
be carriers of gene variants causing an increased risk for
disease, but most of these predisposition genes remain to
be identified. The present study demonstrates genetic
aberrations that are associated with early onset CRC.
Compared to the current literature, the number of
patients (n = 40) is fairly high, and the number of mea-
surements provided is very high.  T o our knowledge no
previous study has at this resolution level compared the
genomic changes between tumors from patients with ~20
year difference in onset.  Methods for genome-wide
Figure 3 Genes mapping to the chromosome bands with copy number aberrations associated with early onset CRC. Chromosomal sites 
gained or lost with statistical significance in the early compared to the late onset tumor group are shown in red or green boxes, respectively. Chro-
mosomes with no aberrations or aberrations in centromere regions only, are shaded. Genes which have expression levels corresponding to chromo-
somal aberration, and concurrently located within the statistically significant regions are indicated within the boxes. Genes which also have 
significantly different expression level between early onset and late onset groups are further marked with green or red background.
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SLC39A8
MANBA
UBE2D3
LOC493856
DHRS6
PPA2
FLJ20184
MGC16169
MGC26963
RPL34
CASP6
PLA2G12A
IF
ENPEP
FLJ39370
C4orf16
TIFA
ALPK1
ARSJ
UGT8
TRAM1L1
hCG39909.2
SEC24D
USP53
LOC401152
FABP2
PDE5A
ANXA5
FLJ35630
NUDT6
PDZK6
HSPA4L
LOC132321
IGFBP2
FLJ46536
MR-1
WNT10A
SLC4A3
NEUROG3
hCG2041592
hCG38404.3 LOC441235|LOC442555Berg et al. Molecular Cancer 2010, 9:100
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assessment of DNA copy number alterations in most
studies published to date are generally of low to medium
resolution. The introduction of aCGH has increased the
resolution hundreds of times, and with the microarra y
platform used in this study the total number of probes is
385 000, giving an average probe interval of 6000 bases.
In addition, measurements of mRNA expression levels
from the same samples have allowed for a short list of
candidate genes.
Genomic alterations in colorectal cancers
The overall DNA copy number profile for CRC found in
the present study is in line with previous reports [19],
suggesting that the series used are representative for mic-
rosatellite stable CRCs. The profile includes frequent
Table 3: Genes/Probe IDs showing statistically significant different DNA copy number and mRNA expression in early 
versus late onset colorectal cancers.
Patients with chromosomal aberrations
Copy number 
aberration
Gene/Probe ID Chromosome 
band
Mbps§ from pter Size# (Kbps) Early onset (n = 23) Late onset (n = 17)
Gain CLC/118354 19q13.2 44.9 6.8 7 0
LTBP4/162965 19q13.2 45.8 30.6 6 0
ZNF574/130858 19q13.2 47.3 11.2 6 0
Loss PPAT/156570 4q12 57.1 42.3 12 3
EIF4E/195966 4q23 100.2 22.1 12 3
RG9MTD2/125412 4q23 100.8 16.9 12 3
PLA2G12A/106464 4q25 111.0 16.5 12 3
§Gene start position, indicated as Mbps from pter
#Gene size, indicated in Kbps
Figure 4 mRNA expression levels of a short list of seven candidate genes for early onset CRC. Log transformed mRNA expression values plotted 
against age. Red bullets indicate copy number gain, green bullets indicate loss and grey bullets indicate normal copy number. Box plots for each of 
the patient groups are indicated for each gene.
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gains at 8q, 13q, and 20q and losses from 4p, 4q, 8p, 17p,
18p and 18q.
As expected the most common loss and gain were
found at 18q and 20q, respectively. The SROs in these
chromosome arms contains a number of protein coding
genes, including well known critical cancer genes as
BCL2 (18q22), DCC (18q21) and AURKA  (20q13). The
latter is known to be important for normal chromosome
segregation, observed as over-expressed in cancers with
chromosomal instability (CIN) [33]. Also present in
20q13 are several members of the SERPIN gene family,
including SERPINB5, positively regulated by TP53 [34].
Furthermore, one of the 10 miRNAs in this region is the
MIR646 (hsa-miR-646), reported to be related to colorec-
tal cancer (The miR-ontology database, http://ferro-
lab.dmi.unict.it/miro) [35].
In CRC, aberrations at chromosome 8 are commonly
reported as loss in 8p and gain in 8q [36]. Our data shows
that the breakpoint is located on the p-arm, approxi-
mately five Mbps from the centromere (Additional file 3).
This is in accordance with findings from others [37,38].
This clearly shows that the resolution of aCGH is crucial
for a more exact evaluation of breakpoint regions. Loss of
gross parts of both arms of chromosome 4 is frequently
reported in several cancers [39-44], and the location of
tumor suppressor genes important for tumorigenesis in
this region is plausible [45]. In this study we observed on
average 40% of losses in chromosome 4.
Differences in genome profile between early onset and late 
onset CRC
In the early onset sample series, the number of chromo-
somal aberrations and the number of breakpoints were
significantly higher than in the late onset sample series.
However, the percentage of measurements showing aber-
rations does not differ significantly. This indicates that
about the same amount of DNA is affected by copy num-
ber changes in the two series, but the number of events is
larger in the early onset group compared to the late onset
samples, which again suggests increased genome instabil-
ity in the early onset tumors.
Fifteen loci at five unique chromosomes were statisti-
cally more often altered in the tumors of the early onset
group compared to the late onset group (Table 2). The
gained region at chromosome 19 with statistically signifi-
cant difference between the two patient groups spanned 4
M b p s .  T h i s  r e g i o n  c o m p r i s e s  m o r e  t h a n  o n e  h u n d r e d
protein coding genes, among them a group of genes in the
carcinoembryonic antigen (CEA) family. Genes in this
family encode pregnancy-specific beta-I-glycoproteins
and carcinoembryonic antigen-related cell adhesion mol-
ecules. Also, 19q13.2-q13.31 contains three microRNAs,
of which one, the MIR641 (hsa-miR-641), is known to be
associated with colorectal cancer [35]. Chromosome 19 is
notable for the highest gene density of all human chro-
mosomes, large clustered gene families and high GC con-
tent, indicating biological and evolutionary significance
[46]. In a recent GWAS study, a region on 19q13.1 was
identified as a putative susceptibility locus for CRC [10].
This region is 6.4 Mbps proximal to the region we have
identified at 19q13.2-q13.31.
In the present study six smaller regions at chromosome
4, comprising ~70 Mbps in total, were identified with sta-
tistical significant losses in the early onset group com-
pared to the late onset patients (Table 2). In total ~250
genes and 30 miRNAs are located in the affected regions.
Even though deletions in chromosome 4 is a common
feature in CRC, and known cancer genes such as KIT,
EGF and FGF2 are situated here, none has yet been veri-
fied as predisposing for early onset or hereditary CRC.
Chromosomal loci previously suggested to contain
genes that may predispose to CRC [4-10] are not the
same as the ones found in the present study. This may
best be explained by the difference in inclusion criteria;
whereas the GWAS-studies have mainly been performed
in samples from individuals from high-risk families, the
present study selected patients with young age at diagno-
sis of disease. Mourra et al. reported a statistically higher
frequency of deleted 14q loci in patients <50 years at pri-
mary diagnosis versus patients >50 years at diagnosis
[11], but this could not be confirmed in the present study.
Integration of DNA copy number and mRNA expression 
data
The integration analysis of genome copy number data
with mRNA expression data identified a short list of 7
target genes differing between the early- and late onset
groups. The three gained and up-regulated genes, CLC,
LTBP4, and ZNF574, were altered in the same tumors.
The CLC gene differentiates the tumor groups the most
with regard to mRNA expression levels (P = 0.001). The
CLC protein (Charcot-Leyden crystal protein/Galectin-
10) is a lysophospholipase in the galectin super family of
proteins, normally expressed in eosinophils and baso-
phils, associated with inflammation and some myeloid
leukemia [47]. However, data on CLC in cancer is sparse.
The LTBP4 protein (latent TGF-β binding protein 4)
has structural roles in the extracellular matrix as well as
its participation in the TGFβ-pathway. TGFβ-pathway
components are commonly altered in cancer in general,
and in colorectal cancer in particular. On of them,
SMAD4, cause juvenile polyposis when mutated in ger-
mline cells. It is localized at chromosome 18q21 together
with SMAD2, in a region frequently deleted in colorectal
cancers. TGFβRII mutations are found in ~30% of col-
orectal cancers and are considered the main mechanism
of inhibition of the TGFβ-pathway. Although mutations
in  TGFβRI  are rare, an association between theBerg et al. Molecular Cancer 2010, 9:100
http://www.molecular-cancer.com/content/9/1/100
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TGFBR1*6A-polymorphism and cancer has been
reported [48]. Together with LAPs (latency-associated
proteins), LTBP4 it is involved in the assembly, secretion
and targeting of TGFβs [49]. TGF-β has an important,
complex and somewhat dual role in the normal cell.
Downstream effects are as diverse as promotion of
migration, adhesion and differentiation on one hand, to
inhibition of growth, cell-cycle control and apoptosis on
the other [50]. As opposed to the present results, others
have reported a suppression of LTBP4 to cause cancer
[51,52]. An increase in LTBP4 expression might poten-
tially cause colorectal cancer development. Elevated lev-
els might increase deposition of TGFβ in extracellular
matrix, thus hindering TGFβ to bind to the receptor, and
thereby prevent tumor suppressive downstream reactions
such as apoptosis, and growth arrest.
The concomitantly lost and down-regulated genes
PPAT, EIF4E, RG9MTD2, and PLA2G12A are located on
different bands of chromosome 4. All these four candi-
date genes and potential tumor suppressor genes had a
combined genomic loss and mRNA under-expression in
the same patients, presumably associated with mono-
somy.  PLA2G12A  is a member of the secreted PLA2s
(sPLA2) in the phospholipase A2 family of proteins,
found to be involved in tumorigenesis [53-55]. The enzy-
matic activity of PLA2s is to hydrolyze the fatty acid from
membrane phospholipids, which are further metabolized
and forms eicosanoids and bioactive lipid mediators [56].
PLA2G12A has been reported to be highly expressed in
normal and tumor tissues from the colon [53], which sug-
gests that reduced expression, as reported in this study,
might contribute to an oncogenic transformation in a
subset of early onset CRCs. The protein EIF4E is a trans-
lation initiation factor, and mRNA expression is reported
to be elevated in many human cancers [57]. mRNA levels
are reported to increase during tumor formation and pro-
gression of colorectal cancers [58]. In our study the
expression of EIF4E was found to be reduced in the early
onset group compared to the late onset group, which may
indicate that early onset cancers develop in an EIF4E
independent manner.
TP53 mutations and genomic complexity
TP53  mutations are associated with CIN tumors. The
TP53 gene was sequenced to confirm an equal represen-
tation of mutations in the two age groups, to ensure that
the series were unbiased. The seemingly high frequency
of 65% mutations reported here is most likely due to the
fact that all protein coding exons in TP53 were analyzed,
and that only microsatellite stable tumors are included in
the study. The samples with loss in 17p13.1 had signifi-
cantly more aberrations throughout the whole genome,
compared to the samples with normal copy number or
gain. This is as expected, partly because loss of 17p is
associated with CIN phenotype, and partly because one
expects any sample with aberration in a given position to
have more aberrations globally. Furthermore, a statisti-
cally significant difference in percentage of aberrations
was seen when comparing mutated (n = 27) to wild type
(n = 13) samples, irrespective of DNA copy number in the
region where TP53 is located. Samples with no aberra-
tions in TP53 showed a lower degree of genetic complex-
ity measured as the copy number level throughout the
genome. This clearly indicates that non-functional TP53,
regardless of how it is inactivated, plays an important role
in tumorigenesis associated with CIN.
Interestingly, loss of 1q21 containing the AMP kinase
subunit β2 (PRKAB2), which was recently shown by the
Arnold Levine laboratory to be regulated by TP53 [59],
are more often lost in tumors with wild type TP53 than in
those with mutated TP53 (P = 0.08).
Cancer susceptibility and genetic pathways
Our finding that carcinomas from early onset patients
present a high number of chromosomal aberrations and
breakpoints is comparable with the concept that they
have inherited a germline mutation in a gene relevant for
chromosome stability, with loss of the second allele
occurring somatically. Relevant examples for such a rela-
tionship are the complex pattern of copy number changes
observed in breast carcinomas associated with germline
BRCA1 mutations (when compared with sporadic breast
carcinomas), and the microsatellite instability observed
in colorectal carcinomas from Lynch syndrome patients
[60-62]. The data we present here highlight possible can-
didate susceptibility loci that complement other studies
using different strategies [5,6,10,21-25,63-66]. Alterna-
t i v e l y ,  t h e  c h a n g e s  w e  h a v e  f o u n d  m o r e  f r e q u e n t  i n
tumors from early onset patients, may reflect changes as
a result of somatic mutations related to a yet uncovered
germline mutation.
Conclusions
This is the first study that has identified distinct tumor
genome profiles in early onset and late onset CRC
patients at 6 Kbps resolution level, combined with the
corresponding mRNA expression profile. Sixteen
genomic loci containing more than 500 coding genes
were identified as preferentially altered in cancers from
early onset patients when compared to late onset
patients. Finally, by integration analysis with gene expres-
sion data from the same samples, we identified a short list
of seven candidate genes as potentially predisposing to
early onset CRC. Further studies are warranted to find
out if early onset CRC is caused by inherited low pene-
trance alleles or germline mutations in these or other
genes.Berg et al. Molecular Cancer 2010, 9:100
http://www.molecular-cancer.com/content/9/1/100
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